Cargando…
Persons living with HIV with advanced HIV disease: need for novel care models
INTRODUCTION: Despite increasing focus on test and treat strategies for people living with HIV (PLHIV), many continue to enrol late in care and initiate antiretroviral therapy (ART) when they have advanced HIV disease. METHODS: We analyzed PLHIV ≥15 years of age starting ART in Ethiopia, Kenya, Moza...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293147/ https://www.ncbi.nlm.nih.gov/pubmed/30549245 http://dx.doi.org/10.1002/jia2.25210 |
_version_ | 1783380497356816384 |
---|---|
author | Teasdale, Chloe A Yuengling, Katharine Preko, Peter Syowai, Maureen Ndagije, Felix Rabkin, Miriam Abrams, Elaine J El‐Sadr, Wafaa M |
author_facet | Teasdale, Chloe A Yuengling, Katharine Preko, Peter Syowai, Maureen Ndagije, Felix Rabkin, Miriam Abrams, Elaine J El‐Sadr, Wafaa M |
author_sort | Teasdale, Chloe A |
collection | PubMed |
description | INTRODUCTION: Despite increasing focus on test and treat strategies for people living with HIV (PLHIV), many continue to enrol late in care and initiate antiretroviral therapy (ART) when they have advanced HIV disease. METHODS: We analyzed PLHIV ≥15 years of age starting ART in Ethiopia, Kenya, Mozambique and Tanzania from 2005 to 2015 based on CD4+ groups at ART initiation (≥200, 100 to 199, 50 to 99 and <50 cells/mm(3)) to examine attrition (loss to follow‐up (LTF) and death) using Kaplan‐Meier estimators and Cox proportional hazards models. LTF was defined as no clinic visit >6 months; deaths were ascertained from medical records. RESULTS AND DISCUSSION: A total of 305,443 PLHIV were included in the analysis: 118,580 (38.8%) CD4+ ≥200, 91,788 (30.1%) CD4+ 100 to 199, 44,029 (14.4%) CD4+ 50 to 99 and 51,046 (16.7%) CD4+ <50 cells/mm(3). At 12 months after ART initiation, attrition for those with CD4+ ≥200, 100 to 199, 50 to 99 and <50 cells/mm(3) was 21.3% (95% CI 21.1 to 21.6), 21.8% (95% CI 21.6 to 22.1), 27.3% (95% CI 26.9 to 27.7) and 33.6% (95% CI 33.2 to 34.0) respectively. In multivariable models, compared to PLHIV with CD4+ ≥200 cells/mm(3), those with CD4+ 50 to 99 cells/mm(3) had 29% increased risk of attrition (adjusted hazard ratio (AHR) 1.29, 95% CI 1.27 to 1.32) and those with <50 cells/mm(3) had 56% increased risk of attrition (AHR 1.56, 95% CI 1.53 to 1.58). Men had higher attrition compared to women across all CD4+ groups and overall were 28% more likely to experience attrition (AHR 1.28, 95% CI 1.26 to 1.29). Even after ART initiation, PLHIV with advanced disease had notably inferior outcomes with substantial gradient within the low CD4+ strata highlighting the need for targeted interventions for these populations. CONCLUSIONS: Greater efforts, including the identification of effective differentiated service delivery models, are needed to ensure that all PLHIV starting treatment can garner the benefits from ART and achieve favourable outcomes. |
format | Online Article Text |
id | pubmed-6293147 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-62931472018-12-18 Persons living with HIV with advanced HIV disease: need for novel care models Teasdale, Chloe A Yuengling, Katharine Preko, Peter Syowai, Maureen Ndagije, Felix Rabkin, Miriam Abrams, Elaine J El‐Sadr, Wafaa M J Int AIDS Soc Short Reports INTRODUCTION: Despite increasing focus on test and treat strategies for people living with HIV (PLHIV), many continue to enrol late in care and initiate antiretroviral therapy (ART) when they have advanced HIV disease. METHODS: We analyzed PLHIV ≥15 years of age starting ART in Ethiopia, Kenya, Mozambique and Tanzania from 2005 to 2015 based on CD4+ groups at ART initiation (≥200, 100 to 199, 50 to 99 and <50 cells/mm(3)) to examine attrition (loss to follow‐up (LTF) and death) using Kaplan‐Meier estimators and Cox proportional hazards models. LTF was defined as no clinic visit >6 months; deaths were ascertained from medical records. RESULTS AND DISCUSSION: A total of 305,443 PLHIV were included in the analysis: 118,580 (38.8%) CD4+ ≥200, 91,788 (30.1%) CD4+ 100 to 199, 44,029 (14.4%) CD4+ 50 to 99 and 51,046 (16.7%) CD4+ <50 cells/mm(3). At 12 months after ART initiation, attrition for those with CD4+ ≥200, 100 to 199, 50 to 99 and <50 cells/mm(3) was 21.3% (95% CI 21.1 to 21.6), 21.8% (95% CI 21.6 to 22.1), 27.3% (95% CI 26.9 to 27.7) and 33.6% (95% CI 33.2 to 34.0) respectively. In multivariable models, compared to PLHIV with CD4+ ≥200 cells/mm(3), those with CD4+ 50 to 99 cells/mm(3) had 29% increased risk of attrition (adjusted hazard ratio (AHR) 1.29, 95% CI 1.27 to 1.32) and those with <50 cells/mm(3) had 56% increased risk of attrition (AHR 1.56, 95% CI 1.53 to 1.58). Men had higher attrition compared to women across all CD4+ groups and overall were 28% more likely to experience attrition (AHR 1.28, 95% CI 1.26 to 1.29). Even after ART initiation, PLHIV with advanced disease had notably inferior outcomes with substantial gradient within the low CD4+ strata highlighting the need for targeted interventions for these populations. CONCLUSIONS: Greater efforts, including the identification of effective differentiated service delivery models, are needed to ensure that all PLHIV starting treatment can garner the benefits from ART and achieve favourable outcomes. John Wiley and Sons Inc. 2018-12-13 /pmc/articles/PMC6293147/ /pubmed/30549245 http://dx.doi.org/10.1002/jia2.25210 Text en © 2018 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Reports Teasdale, Chloe A Yuengling, Katharine Preko, Peter Syowai, Maureen Ndagije, Felix Rabkin, Miriam Abrams, Elaine J El‐Sadr, Wafaa M Persons living with HIV with advanced HIV disease: need for novel care models |
title | Persons living with HIV with advanced HIV disease: need for novel care models |
title_full | Persons living with HIV with advanced HIV disease: need for novel care models |
title_fullStr | Persons living with HIV with advanced HIV disease: need for novel care models |
title_full_unstemmed | Persons living with HIV with advanced HIV disease: need for novel care models |
title_short | Persons living with HIV with advanced HIV disease: need for novel care models |
title_sort | persons living with hiv with advanced hiv disease: need for novel care models |
topic | Short Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293147/ https://www.ncbi.nlm.nih.gov/pubmed/30549245 http://dx.doi.org/10.1002/jia2.25210 |
work_keys_str_mv | AT teasdalechloea personslivingwithhivwithadvancedhivdiseaseneedfornovelcaremodels AT yuenglingkatharine personslivingwithhivwithadvancedhivdiseaseneedfornovelcaremodels AT prekopeter personslivingwithhivwithadvancedhivdiseaseneedfornovelcaremodels AT syowaimaureen personslivingwithhivwithadvancedhivdiseaseneedfornovelcaremodels AT ndagijefelix personslivingwithhivwithadvancedhivdiseaseneedfornovelcaremodels AT rabkinmiriam personslivingwithhivwithadvancedhivdiseaseneedfornovelcaremodels AT abramselainej personslivingwithhivwithadvancedhivdiseaseneedfornovelcaremodels AT elsadrwafaam personslivingwithhivwithadvancedhivdiseaseneedfornovelcaremodels |